SCHEMBL208995

SCHEMBL208995

CC(C)N1CCN(C(=O)c2ccc(-c3cc(Cl)c(CC4CCN(C5CCC(O[Si](C)(C)C(C)(C)C)CC5)C4=O)c(Cl)c3)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.40
HRH3 Q9Y5N1 16/20 0.37
CHRNA7 P36544 1/20 0.36
SLC6A4 P31645 3/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A3 Q01959 1/20 0.35
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208996 1.00 MET (0.40) METHRH3CHRNA7SLC6A4SLC6A2
SCHEMBL211810 0.92 HRH1 (0.33) METHRH3SLC6A4PIK3CAMTOR
SCHEMBL209533 0.92 HRH1 (0.33) METHRH3SLC6A4PIK3CAMTOR
SCHEMBL209534 0.92 HRH1 (0.33) METHRH3SLC6A4PIK3CAMTOR
SCHEMBL209532 0.92 HRH1 (0.33) METHRH3SLC6A4PIK3CAMTOR
SCHEMBL210979 0.91 HRH3 (0.40) METHRH3SLC6A4SLC6A2SLC6A3
SCHEMBL208200 0.91 HRH3 (0.40) METHRH3SLC6A4SLC6A2SLC6A3
SCHEMBL210980 0.91 HRH3 (0.40) METHRH3SLC6A4SLC6A2SLC6A3
SCHEMBL209200 0.90 HDAC4 (0.41)
SCHEMBL210501 0.90 LRRK2 (0.34) METHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US disclosed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US disclosed
EP-2016047-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-01-21 EP disclosed
WO-2007124337-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 MET 2704/4885HRH3 1964/4885CHRNA7 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.